Altre lingue Shilpa Medicare Limited

Azioni

SHILPAMED

INE790G01031

Tempo differito Bombay S.E. Altri mercati azionari 09:49:50 26/06/2024			Variaz. 5gg	Var. 1 gen.
580,5 ^INR	-1,60%		+10,10%	+75,85%

25/06	L'unità di bioanalisi di Shilpa Medicare ottiene la classificazione "Nessuna azione indicata" dalla FDA statunitense	MT
24/05	Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Shilpa Medicare Bio Analytical Unit Gets "No Action Indicated" Classification from US FDA	25/06
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	23/05
Shilpa Medicare Limited Announces Successful Completion of Early Clinical Development and Ongoing Phase 3 Clinical Trial of Its Newly Developed Drug "SML-007", for the Treatment of Non-Alalcoholic Fatty Liver Disease	14/05
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	18/04
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	17/04
Shilpa Medicare Gets Board Nod to Launch QIP	09/04
Shilpa Medicare's Life Science Arm Names CEO	28/03
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA	01/03
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe	26/02
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug	19/01
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	10/11
Shilpa Medicare Acquires US-Based Pilnova Pharma	03/11
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal	11/10/23
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection	04/09/23
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms	04/09/23
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg	01/09/23
Shilpa Medicare's Manufacturing Facility in Telangana Gets Clearance from Brazilian Regulator	25/08/23
Shilpa Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	10/08/23
Shilpa Medicare Limited Announces Issuance of Redeemable Non-Convertible Debentures for its 2 Wholly Owned Subsidiaries	08/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Shilpa Medicare Limited

Azioni

SHILPAMED

INE790G01031

Altre lingue

Filtri